Malik Fady Ibraham 4

What Happened Malik Fady Ibraham, a director of Rocket Pharmaceuticals, received equity awards on June 18, 2026: 22,862 restricted stock units (RSUs) and a derivative grant representing rights to purchase 64,860 shares. Both grants were reported at $0.00 (no cash paid at grant). The RSUs convert one-for-one into common shares, and the option-like award gives the right to buy 64,860 shares once vested.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-07-06 (appears late vs. the typical 2-business-day filing requirement).
• Grant types/code: A = Award/Grant. RSUs (22,862) and derivative option right (64,860).
• Price: $0.00 reported for both awards (standard for compensation grants).
• Vesting: Both awards vest in full and become exercisable/convertible on June 18, 2027 (per footnotes).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 = RSUs convert 1:1 to common stock; F2 = option right to purchase 64,860 shares, vesting/exercisable 6/18/2027.

Context These are compensation awards (not open-market purchases or sales) and do not indicate an immediate buy or sell. The derivative award is a future right to purchase shares once vested; it was not exercised. The late filing may affect timeliness transparency but does not change the nature of the grants.